Agile Thrpe
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.07
- Today's High:
- $2.3
- Open Price:
- $2.23
- 52W Low:
- $0.175
- 52W High:
- $11.396
- Prev. Close:
- $2.25
- Volume:
- 22000
Company Statistics
- Market Cap.:
- $10.82 million
- Book Value:
- 0.16
- Revenue TTM:
- $8.40 million
- Operating Margin TTM:
- -677.39%
- Gross Profit TTM:
- $-6617000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -129.01%
- Return on Equity TTM:
- -791.13%
Company Profile
Agile Thrpe had its IPO on 2014-05-23 under the ticker symbol AGRX.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Agile Thrpe has a staff strength of 30 employees.
Stock update
Shares of Agile Thrpe opened at $2.23 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.07 - $2.3, and closed at $2.14.
This is a -4.89% slip from the previous day's closing price.
A total volume of 22,000 shares were traded at the close of the day’s session.
In the last one week, shares of Agile Thrpe have slipped by -14.74%.
Agile Thrpe's Key Ratios
Agile Thrpe has a market cap of $10.82 million, indicating a price to book ratio of 1.2457 and a price to sales ratio of 0.9136.
In the last 12-months Agile Thrpe’s revenue was $8.40 million with a gross profit of $-6617000 and an EBITDA of $-54896000. The EBITDA ratio measures Agile Thrpe's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Agile Thrpe’s operating margin was -677.39% while its return on assets stood at -129.01% with a return of equity of -791.13%.
In Q3, Agile Thrpe’s quarterly earnings growth was a positive 0% while revenue growth was a positive 133.3%.
Agile Thrpe’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-11.23 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Agile Thrpe’s profitability.
Agile Thrpe stock is trading at a EV to sales ratio of 0.452 and a EV to EBITDA ratio of -0.0576. Its price to sales ratio in the trailing 12-months stood at 0.9136.
Agile Thrpe stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $18.46 million
- Total Liabilities
- $11.65 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $126000
- Dividend Payout Ratio
- 0%
Agile Thrpe ended 2024 with $18.46 million in total assets and $0 in total liabilities. Its intangible assets were valued at $18.46 million while shareholder equity stood at $6.34 million.
Agile Thrpe ended 2024 with $0 in deferred long-term liabilities, $11.65 million in other current liabilities, 4000.00 in common stock, $-430771000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.15 million and cash and short-term investments were $6.15 million. The company’s total short-term debt was $1,595,000 while long-term debt stood at $0.
Agile Thrpe’s total current assets stands at $15.49 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $3.71 million compared to accounts payable of $4.91 million and inventory worth $1.80 million.
In 2024, Agile Thrpe's operating cash flow was $0 while its capital expenditure stood at $126000.
Comparatively, Agile Thrpe paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.14
- 52-Week High
- $11.396
- 52-Week Low
- $0.175
- Analyst Target Price
- $3
Agile Thrpe stock is currently trading at $2.14 per share. It touched a 52-week high of $11.396 and a 52-week low of $11.396. Analysts tracking the stock have a 12-month average target price of $3.
Its 50-day moving average was $2.58 and 200-day moving average was $7.55 The short ratio stood at 0.64 indicating a short percent outstanding of 0%.
Around 15.9% of the company’s stock are held by insiders while 354.1% are held by institutions.
Frequently Asked Questions About Agile Thrpe
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Agile Therapeutics, Inc., a women’s healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.